Henry Schein HSIC
United StatesHealthcare · Medical DistributionUSD
97.27 USD (+16.3%)
15 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Henry Schein is a global distributor of healthcare products and services, primarily dentistry and medicine, acting as an intermediary between manufacturers and healthcare professionals.
Key points
from its scores- ✓Good share-price trend8.8
- ✓Favourable backdrop7.1
- ✕Little or no dividend1.5
- ✕Fragile balance sheet4.2
- ✕Little competitive advantage4.9
AI analysis
bottom line, main risk, context and newsValuation is reasonable and growth is stable, but elevated debt and thin margins justify waiting for balance sheet improvement before increasing exposure.
Henry Schein shows a solid healthcare distributor profile with earnings growth of 17.10% and an attractive forward P/E of 13.97, although its net debt of 3.39x EBITDA and operating margin of 5.76% cap the financial health score. The 39.88% 12-month momentum reflects market confidence in its execution.
Leverage of 3.39x EBITDA with operating margins of 5.76% leaves little cushion against a sustained rise in rates or a slowdown in healthcare spending that could compress margins further.
Context and risks
No recent relevant news and no material exposure to current macro factors. There is no specific regulatory, geopolitical, or business model risk justifying an additional adjustment.
Is Henry Schein stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 24.4 | 26.7 | −9% |
| EV / EBITDA | 13.5 | 14.5 | −7% |
| Price / book | 3.0 | 4.1 | −28% |
| Price / sales | 0.7 | 3.4 | −79% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.6 out of 10 (median for Healthcare: 4.7).
Average analyst target: 97.27 USD, +16.3% versus the price.
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 24.4
- Forward P/E
- 14.0
- EV / EBITDA
- 13.5
- Price / book
- 3.0
- Price / sales
- 0.7
- PEG
- 1.69
- Market cap
- 9.5B USD
- Enterprise value
- 14.5B USD
Profitability
- ROE
- 8.9%
- ROA
- 4.4%
- ROIC (approx.)
- 11.1%
- Gross margin
- 31.3%
- Operating margin
- 5.8%
- Net margin
- 3.0%
- Free cash flow
- 446.0M USD
- FCF yield
- 4.7%
- Cash conversion
- 41%
Solvency
- Total debt
- 3.8B USD
- Net debt
- 3.7B USD
- Cash
- 157.0M USD
- EBITDA
- 1.1B USD
- Net debt / EBITDA
- 3.39
- Debt / equity
- 80.73
- Current ratio
- 1.32
- Quick ratio
- 0.55
Growth
- Revenue growth
- +6.7%
- Earnings growth
- +17.1%
- EPS (TTM)
- 3.43 USD
- EPS (forward)
- 5.99 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.84
- Analyst consensus
- Buy (15)
- Target price
- 97.27 USD
- 52-week range
- 61.95 – 92.18
Recent news
All HSIC news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Henry Schein
Is Henry Schein stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 5.6 out of 10 (median for Healthcare: 4.7). Average analyst target: 97.27 USD, +16.3% versus the price. This is not investment advice.
What score does Henry Schein get on MeridIAn Screener?
It scores 5.5 out of 10, rank 1,403 of 2,130 (better than 32% of the companies analysed). Its strongest category is Momentum (8.8) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Henry Schein's P/E ratio?
Its P/E is 24.4: the share price equals 24.4 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 14.0.
How much is Henry Schein worth on the stock market?
Its market capitalisation is 9.5B USD and its enterprise value, debt included, is 14.5B USD.
How much debt does Henry Schein have?
Its net debt (debt minus cash) is 3.7B USD. That is 3.39 times its EBITDA; the Healthcare median is 1.53.
Does Henry Schein pay a dividend?
It pays no dividend, or almost none.
How has Henry Schein stock performed over the last year?
It has risen 32.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 61.95 and 92.18 USD. Past performance does not guarantee future results.
What do analysts think of Henry Schein?
15 analysts cover it; their average recommendation is “Buy” and their average target is 97.27 USD (+16.3% versus the price). It is an estimate, not market data.